Search for: "Sandoz GmbH"
Results 1 - 20
of 68
Sorted by Relevance
|
Sort by Date
7 Jul 2020, 9:15 am
Sandoz, Inc., Sandoz International GMBH, Sandoz GMBH, holding that Sandoz failed to prove that the asserted claims were invalid for obviousness-type double patenting (ODP), failure to meet the written description requirement, and obviousness for lack of motivation to combine... [read post]
19 May 2016, 8:56 pm
• Defendants: Sandoz Inc.; Sandoz International GmbH; Sandoz GmbH; Lek Pharmaceuticals, d.d. [read post]
7 Jul 2020, 9:15 am
Sandoz, Inc., Sandoz International GMBH, Sandoz GMBH, holding that Sandoz failed to prove that the asserted claims were invalid for obviousness-type double patenting (ODP), failure to meet the written description requirement, and obviousness for lack of motivation to combine the prior art references. [read post]
9 Aug 2009, 4:54 pm
Sandoz Inc. v. [read post]
26 Jul 2007, 9:48 pm
By Donald Zuhn -- Last month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) approved three new follow-on biologic drugs: Binocrit (Sandoz GmbH), Epoetin alfa Hexal (Hexal Biotech Forschungs GmbH), and Abseamed (Medice Arzneimittel Pütter GMBH Co.). [read post]
15 Mar 2015, 8:48 pm
• Defendants: Sandoz Private Ltd.; Sandoz International GmbH Infringement of U.S. [read post]
12 Feb 2012, 8:34 pm
Laboratories, Inc., Purdue Pharmaceuticals L.P., Rhodes Technologies, Board of Regents of the University of Texas Systems, Grunenthal GMBH • Defendant: Sandoz Inc. [read post]
16 Sep 2010, 9:54 pm
Foreign defendants Sandoz International GmbH and Novartis were... [read post]
15 Feb 2019, 12:47 am
The judgment was handed down in an invalidation action brought by Sandoz International GmbH. [read post]
11 Nov 2015, 3:22 pm
On Monday this Kat posted "When litigants must be responsible -- and what happens when they're not: Lyrica pregabalin injunction is continued" (here), this being a short note on the decision of Mr Justice Arnold in Warner-Lambert Co LLC v Sandoz GmbH, Sandoz Ltd and Lloyds Pharmcacy Ltd [2015] EWHC 3153 (Pat), in the Patents Court, England and Wales, to extend an interim injunction in an ongoing patent infringement dispute over pregabalin, a generic… [read post]
3 Apr 2009, 1:46 am
On Wednesday, while much of the IP world was amusing itself with April Fool pranks, the Court of Appeal (England and Wales) had more serious matters to resolve when it gave its decision in Napp Pharmaceutical Holdings Ltd v ratiopharm GmbH/Napp Pharmaceutical Holdings Ltd v Sandoz Ltd [2009] EWCA Civ 252. [read post]
20 Sep 2016, 1:03 am
Moderator Dominic Adair (Partner, Bristows (UK)) led his panellists Fritz Reiter (Regulatory CMC Team Leader, Sandoz GmbH (AT)), Prof. [read post]
9 Nov 2015, 3:41 pm
Warner-Lambert Co LLC v Sandoz GmbH, Sandoz Ltd and Lloyds Pharmcacy Ltd [2015] EWHC 3153 (Pat) is the latest in a series of decisions in the ongoing patent infringement dispute over pregabalin, a generic version of Lyrica. [read post]
19 Oct 2012, 6:13 pm
Assets related to four of the markets would be divested to Sandoz International GmbH, a subsidiary of Novartis AG. [read post]
17 Nov 2015, 12:34 am
* When litigants must be responsible -- and what happens when they're not: Lyrica pregabalin injunction is continuedWarner-Lambert Co LLC v Sandoz GmbH, Sandoz Ltd and Lloyds Pharmcacy Ltd [2015] EWHC 3153 (Pat) is the latest in a series of decisions in the ongoing patent infringement dispute over pregabalin, a generic version of Lyrica. [read post]
30 Nov 2015, 3:34 am
Never Too Late 70 [week ending on Sunday 1 November] – Case T-309/13 Enosi Mastichoparagogon Chiou v OHIM, Gaba International Holding GmbH | Sixteen millions IPKats | Tomaydo-Tomahhdo LLC v George Vozray et al | Lookalike packaging | Parasite copying | 3D printing | Labouring the point? [read post]
6 Feb 2013, 12:00 am
Bodenseewerk Perkin-Elmer GmbH, 386 F.3d 1133, 1138 (Fed. [read post]
13 Mar 2013, 4:45 am
Companies Agree to Sell Rights to 18 Drugs to Satisfy FTCThe Federal Trade Commission will require Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.... [read post]
15 Jan 2013, 11:33 am
Companies Agree to Sell Rights to 18 Drugs to Satisfy FTCThe Federal Trade Commission will require Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.... [read post]
3 Feb 2015, 10:53 am
” In re Papst Licensing GmbH & Co. [read post]
